Larimar Therapeutics, Inc. (LRMR)
2.25
-0.02
(-0.88%)
USD |
NASDAQ |
Oct 23, 11:02
Larimar Therapeutics EPS Diluted (Quarterly) : -0.3141 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3141 |
| March 31, 2026 | -0.3281 |
| December 31, 2025 | -0.7316 |
| September 30, 2025 | -0.6092 |
| June 30, 2025 | -0.4089 |
| March 31, 2025 | -0.4578 |
| December 31, 2024 | -0.4517 |
| September 30, 2024 | -0.2429 |
| June 30, 2024 | -0.339 |
| March 31, 2024 | -0.2736 |
| December 31, 2023 | -0.2959 |
| September 30, 2023 | -0.2064 |
| June 30, 2023 | -0.1906 |
| March 31, 2023 | -0.1487 |
| December 31, 2022 | -0.2147 |
| September 30, 2022 | -0.3743 |
| June 30, 2022 | -0.4726 |
| March 31, 2022 | -0.4876 |
| December 31, 2021 | -0.4981 |
| September 30, 2021 | -0.9189 |
| June 30, 2021 | -0.7882 |
| March 31, 2021 | -0.7557 |
| December 31, 2020 | -0.8885 |
| September 30, 2020 | -0.6427 |
| June 30, 2020 | -1.208 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.096 |
| December 31, 2019 | -11.97 |
| September 30, 2019 | -17.00 |
| June 30, 2019 | -7.297 |
| March 31, 2019 | -4.217 |
| December 31, 2018 | -4.721 |
| September 30, 2018 | -4.937 |
| June 30, 2018 | -6.867 |
| March 31, 2018 | -6.952 |
| December 31, 2017 | -5.76 |
| September 30, 2017 | -5.52 |
| June 30, 2017 | -5.88 |
| March 31, 2017 | -5.76 |
| December 31, 2016 | -4.56 |
| September 30, 2016 | -6.48 |
| June 30, 2016 | -6.60 |
| March 31, 2016 | -7.80 |
| December 31, 2015 | -10.20 |
| September 30, 2015 | -8.76 |
| June 30, 2015 | -7.92 |
| March 31, 2015 | -6.36 |
| December 31, 2014 | -5.76 |
| September 30, 2014 | -6.744 |
| June 30, 2014 | -35.52 |
| March 31, 2014 | -2.069 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.78M |
| Total Expenses (Quarterly) | 32.78M |
| Enterprise Value | 85.64M |
| Earnings Yield | -88.13% |
| Normalized Earnings Yield | -88.13 |